Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Proposed Amendment of PAL Would Require Submission of Package Inserts: Mr Kikura
January 23, 2012
- Huge Drop in Compliance Rate for “Explanations in Writing” in Sales of Class 1 OTC Drugs: MHLW Undercover Survey
January 20, 2012
- PMDA to Introduce Direct ADR Reporting System for Patients on Trial Basis
January 20, 2012
- Prof. Nakamura of Keio Univ. Sees Orphan Drug Development Strategy as Reason for Revised Re-pricing Policy
January 20, 2012
- EMA Initiates Review of Oral MS Treatment Gilenya Following Reports of Heart Problems
January 20, 2012
- PAFSC’s Second Committee on Drugs to Review Kyowa Kirin’s ATL Treatment on February 1
January 19, 2012
- PMDA to Expand PGx, Biomarker Consultation System
January 19, 2012
- MHLW Considering “Partial Introduction” of Medico-Economic Evaluation in FY2014
January 18, 2012
- No Serious Concerns Observed for 4 Vaccines: MHLW Study Groups
January 17, 2012
- US Industry Opinion Divided on Japan’s Participation in TPP Talks
January 17, 2012
- PAFSC’s First Committee on Drugs to Review Zyprexa for Depression in Bipolar Disorder on January 27
January 16, 2012
- MHLW Proposes New Fee for Medical Management of Treatment-Resistant Schizophrenia
January 16, 2012
- MHLW Director Tawaragi Raises 3 Points, Including Risk Management Planning, as Priority Measures for FY2012
January 13, 2012
- MHLW to Strengthen Support for Ultra-Orphan Drug Development
January 13, 2012
- PFSB Calls for Revision of Package Inserts for 15 Products
January 12, 2012
- MHLW Revises Ministerial Ordinance to Prohibit Dispensing Point Services by Pharmacies
January 12, 2012
- MHLW Issues Administrative Notification on Reexamination Period for 8 Products Approved After Partial Changes
January 11, 2012
- MHLW Issues Notification on Change in Clinical Trial Protocols
January 11, 2012
- Nicotine Patch Products Should Remain Class 1 OTC Drugs: PAFSC Subcommittee
January 11, 2012
- JPO Amends Patent Examination GL to Allow Patent Extension for New Formulations Containing Existing APIs
January 10, 2012
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…